罗格列酮对2型糖尿病患者胰岛素敏感性及超敏C-反应蛋白的影响

Effects of Rosiglitazone on Insulin Sensitivity and High Sensitive C-Reactive Protein in Patients with Type 2 Diabetes Mellitus

目的:探讨马来酸罗格列酮(RSG)对2型糖尿病患者胰岛素敏感性及超敏C-反应蛋白(hs-CRP)的影响。方法:测定血糖控制不佳的50例2型糖尿病患者应用RSG(4mg/d)前及12周后空腹血糖(FPG)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)、胰岛素敏感指数(IAI)、hs-CRP,并对治疗前后数值进行统计学比较。结果:RSG治疗12周后FPG、FINS、HOMA-IR、hs-CRP明显下降(均P<0.01),IAI较治疗前升高(P<0.05),差异有统计学意义;hs-CRP与FPG(r=0.596,P<0.01)、FINS(r=0.675,P<0.01)、HOMA-IR(r=0.412,P<0.01)呈正相关,与IAI(r=-0.359,P<0.05)呈负相关。结论:应用RSG在改善胰岛素抵抗的同时可显著降低hs-CRP,从而延缓糖尿病及其大血管并发症的发生和发展。

Objective： To investigate the effects of rosiglitazone on insulin sensitivity and high sensitive C-reactive protein （hs-CRP） in patients with type 2 diabetes mellitus. Methods： The levels of fasting blood glucose （FPG）.fasting insulin （FINS）, homeostasis model assessment indexes （HOMA-IR）, insulin sensitivity indexes （IAl）, and hs-CRP were measured in 50 patients with type 2 diabetes mellitus with poorly controlled blood glucose before the use of 4 mg RSG per day and 12 weeks after the treatment. Results： There was a significant decrease in FPG, FINS, HOMA-IR and hs-CRP （P 〈 0.01）, and a significant increase in IAI （P 〈 0.05）. There was a positive correlation between hs-CRP and FPG （r = 0.596, P 〈 0.01）, FINS （r = 0.675, P 〈 0.01）, and HOMA-IR （r = 0.412, P 〈 0.01）. There was a negative correlation between hs-CRP and IAI （r = -0.359, P 〈 0.05）. Conclusion： The treatment of RSG can not only improve insulin sensitivity but also decrease the level of hs-CRP. RSG can prevent the development of diabetes melleius and macrovascular disease complications.